...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis.
【24h】

Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis.

机译：布洛芬对阿司匹林抑制血小板聚集的程度和持续时间的影响：中风预防的临床后果。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study was designed to measure the magnitude and duration of inhibition of platelet aggregation following doses of aspirin or ibuprofen alone or taken in combination in a group of healthy volunteers. Ten normal volunteer subjects underwent 3 randomized treatment sessions: aspirin 325 mg alone, ibuprofen 400 mg alone, and ibuprofen 400 mg, followed by dosing with aspirin 325 mg 2 hours thereafter. In addition, a confirmatory study was performed in patients. Over 27 months, a cohort of patients treated with aspirin for secondary stroke prophylaxis while concomitantly taking a nonsteroidal anti-inflammatory drug (NSAID) was identified. A significant reduction was found in both the magnitude and duration of aspirin's inhibitory effect on platelet aggregation when ibuprofen was given prior to aspirin administration in normal volunteer subjects. During a 27-month period, a cohort of 28 patients took regular daily doses of ibuprofen or naproxen. Of these 28 patients, 18 returned for follow-up testing in the absence of this pharmacodynamic interaction. None of these 18 patients demonstrated inhibition of platelet aggregation while on both NSAID and aspirin; however, all showed inhibition of aggregation following discontinuation of the NSAID. Notably, 13 of these 18 patients (72%) had experienced a recurrent ischemic episode while taking aspirin and NSAIDs concomitantly. These data suggest that ibuprofen prevents the irreversible inhibition of platelet aggregation produced by aspirin needed for secondary stroke prophylaxis, and this interaction can have clinical consequences for patients taking aspirin.
机译：本研究旨在测量单独服用阿司匹林或布洛芬或在一组健康志愿者中联合服用后对血小板聚集的抑制程度和持续时间。十名正常志愿者受试者接受了3次随机治疗：阿司匹林325 mg，布洛芬400 mg和布洛芬400 mg，然后在2小时后服用325 mg阿司匹林。另外，对患者进行了验证性研究。在超过27个月的时间内，确定了一组接受阿司匹林治疗的患者，以预防继发中风，同时服用非甾体类抗炎药（NSAID）。在正常志愿者受试者中，在服用阿司匹林前给予布洛芬对阿司匹林的血小板凝集的抑制作用的幅度和持续时间均显着降低。在27个月的时间里，队列的28名患者每天定期服用布洛芬或萘普生。在这28名患者中，有18名在没有药效学相互作用的情况下返回随访测试。在这18例患者中，没有一个对NSAID和阿司匹林同时显示抑制血小板凝集的作用。但是，所有药物在停用NSAID后均显示出聚集抑制作用。值得注意的是，这18例患者中有13例（72％）在同时服用阿司匹林和NSAIDs时经历了缺血性发作。这些数据表明，布洛芬可预防不可逆性抑制二次卒中预防所需的阿司匹林产生的血小板凝集，这种相互作用对服用阿司匹林的患者可能产生临床后果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号